LJI308
LJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and dissemination. LJI308 specifically targeted transformed cells as it had little effect on the non-tumorigenic parental HMECs. Targeting RSK using specific and potent inhibitors, such as LJI308, delivers the promise of inhibiting the growth of TNBC.
Product Specifications
CAS Number
1627709-94-7
Product Name Alternative
LJI308 | LJI-308 | LJI 308 | NVP-LJI308 | NVP-LJI-308
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 32 mg/mL 86.87 mM
Smiles
Oc1c (F) cc (cc1F) -c1cnccc1-c1ccc (cc1) N1CCOCC1
Molecular Formula
C21H18F2N2O2
Molecular Weight
368.38
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2,6-Difluoro-4-[4-[4- (4-morpholinyl) phenyl]-3-pyridinyl]-phenol
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7009417-01 0.02 mg
Recombinant Streptococcus pneumoniae ATP synthase subunit c (atpE)
Sign In for Pricing
View Details MBS7009417-02 0.1 mg
Recombinant Streptococcus pneumoniae ATP synthase subunit c (atpE)
Sign In for Pricing
View Details MBS7009417-03 5x 0.1 mg
Recombinant Streptococcus pneumoniae ATP synthase subunit c (atpE)
Sign In for Pricing
View Details